



Monographs

Series Editor: U.Veronesi

The European School of Oncology gratefully acknowledges sponsorship for the Task Force
received from



Pharmaceuticals

A. Goldhirsch (Ed.)

Endocrine Therapy of Breast Cancer V

With 33 Figures and 20 Tables



Springer-Verlag
Berlin Heidelberg New York
London Paris Tokyo
Hong Kong Barcelona
Budapest

A. GOLDBIRSCHE

Department of Medical Oncology
Ospedale Civico
via Tesserete 46
6900 Lugano, Switzerland

ISBN-13: 978-3-642-77664-9 e-ISBN-13: 978-3-642-77662-5
DOI: 10.1007/978-3-642-77662-5

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilm or in any other way, and storage in data banks. Duplication of this publication or parts thereof is permitted only under the provisions of the German Copyright Law of September 9, 1965, in its current version, and permission for use must always be obtained from Springer-Verlag. Violations are liable for prosecution under the German Copyright Law.

© Springer-Verlag Berlin Heidelberg 1992
Softcover reprint of the hardcover 1st edition 1992

The use of general descriptive names, registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Product liability: The publishers cannot guarantee the accuracy of any information about dosage and application contained in this book. In every individual case the user must check such information by consulting the relevant literature.

Typesetting: Camera ready by editor
Printing: Druckhaus Beltz, Hemsbach/Bergstr.; Binding: J. Schäffer GmbH & Co. KG, Grunstadt
23/3145-5 4 3 2 1 0 – Printed on acid-free paper

Foreword

The European School of Oncology came into existence to respond to a need for information, education and training in the field of the diagnosis and treatment of cancer. There are two main reasons why such an initiative was considered necessary. Firstly, the teaching of oncology requires a rigorously multidisciplinary approach which is difficult for the Universities to put into practice since their system is mainly disciplinary orientated. Secondly, the rate of technological development that impinges on the diagnosis and treatment of cancer has been so rapid that it is not an easy task for medical faculties to adapt their curricula flexibly.

With its residential courses for organ pathologies and the seminars on new techniques (laser, monoclonal antibodies, imaging techniques etc.) or on the principal therapeutic controversies (conservative or mutilating surgery, primary or adjuvant chemotherapy, radiotherapy alone or integrated), it is the ambition of the European School of Oncology to fill a cultural and scientific gap and, thereby, create a bridge between the University and Industry and between these two and daily medical practice.

One of the more recent initiatives of ESO has been the institution of permanent study groups, also called task forces, where a limited number of leading experts are invited to meet once a year with the aim of defining the state of the art and possibly reaching a consensus on future developments in specific fields of oncology.

The ESO Monograph series was designed with the specific purpose of disseminating the results of these study group meetings, and providing concise and updated reviews of the topic discussed.

It was decided to keep the layout relatively simple, in order to restrict the costs and make the monographs available in the shortest possible time, thus overcoming a common problem in medical literature: that of the material being outdated even before publication.

UMBERTO VERONESI
Chairman Scientific Committee
European School of Oncology

Contents

Introduction	
A. GOLDBIRSCH	1
Normal Cell Lineages and the Phenotype of the Breast Cancer Cell	
J. TAYLOR-PAPADIMITRIOU	3
The Oestrogen-Regulated pS ₂ -BCEI Protein in Breast Cancer	
E. MILGROM	17
Do All Roads Lead to the Oestrogen Receptor?	
V. C. JORDAN	23
Tamoxifen for the Treatment of Breast Cancer in the Premenopausal Patient	
V. C. JORDAN	29
The Multi-Drug Resistance Phenotype and its Reversal by Drugs (with Special Emphasis on Anti-Oestrogens)	
S. B. KAYE	35
New Endocrine Agents for Breast Cancer	
A. MANNI	45
Prognostic Factors in Primary Breast Cancer: Second Thoughts	
S. M. THORPE and C. ROSE	53
The Contribution of Perturbed Epithelial-Mesenchymal Interactions to Cancer Pathogenesis	
S. L. SCHOR, A. M. SCHOR, A. HOWELL, A. M. GREY, M. PICARDO, I. ELLIS, and G. RUSHTON	61
Reporting Results from Adjuvant Therapy Trials with Special Emphasis on Quality-of-Life Findings	
R. D. GELBER, M. CASTIGLIONE, C. HÜRNY, J. BERNHARD, A. COATES and A. GOLDBIRSCH	73
Adjuvant Chemoendocrine Therapies in Pre- and Postmenopausal Breast Cancer	
A. GOLDBIRSCH, M. CASTIGLIONE and R. D. GELBER	89